-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 18, Roche's Shanghai biopharmaceutical production base with an investment of 2.04 billion yuan was officially completed. The base has a construction area of about 25,000 square meters. It is Roche's second innovative drug production base in China. It is also the first base for a multinational pharmaceutical company to achieve localized production of macromolecular antibody biopharmaceuticals in China. According to the plan, the base will achieve localized sub-packaging of the ophthalmic monoclonal antibody drug Luoshijia by mid-2028, and fully implement aseptic filling production by the end of 2030.
Share
Listen to the news
On November 18, Roche's Shanghai biopharmaceutical production base with an investment of 2.04 billion yuan was officially completed. The base has a construction area of about 25,000 square meters. It is Roche's second innovative drug production base in China. It is also the first base for a multinational pharmaceutical company to achieve localized production of macromolecular antibody biopharmaceuticals in China. According to the plan, the base will achieve localized sub-packaging of the ophthalmic monoclonal antibody drug Luoshijia by mid-2028, and fully implement aseptic filling production by the end of 2030.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending